• Free for qualified executives and consultants to industry

  • Receive quarterly issues of Area Development Magazine and special market report and directory issues


Germany-Based Boehringer Ingelheim Expands Athens, Georgia, Animal Health Operations

Germany-Based Boehringer Ingelheim, a global research-driven pharmaceutical development and manufacturing company, will expand its Animal Health Global Innovation center in Athens, Georgia. The $55 million project is expected to create 55 jobs.

The investment will increase laboratory space and bring additional research and development capabilities and activities to the site. Construction began recently on a 63,000-square-foot facility, located at 1730 Olympic Drive, that will connect two existing buildings currently housing laboratory and administrative space. The new facility is slated to be complete in spring 2024.

“Our new and expanded space has been specifically designed to encourage closer connections between teams and colleagues. After working in a distanced or virtual manner for so many months, we all have a much greater appreciation for the power of both formal and spontaneous collaboration,” explained Caroline Belmont, US Head of Global Innovation. “The significant investment in expanding and enhancing our Athens Global Innovation site will provide not only a comfortable and flexible physical space that inspires collaboration, but also will bring many new tools and technologies to spark the innovation that will ultimately help improve animal and human wellbeing.”

As a world-leading, research-driven pharmaceutical company, Boehringer Ingelheim focuses on three business areas: Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. The company manufactures well-respected and widely used vaccines, parasite-control products, and therapeutics for pets, horses, and livestock.

“Through the successful growth and addition of companies like Boehringer Ingelheim, Georgia continues to establish itself as a growing hub for research and innovation within the life sciences industry,” said GDEcD Commissioner Pat Wilson. “Boehringer Ingelheim has long been an important part of our life sciences community in Georgia, leveraging innovative connections and resources across the University System of Georgia to perform cutting-edge research into the prevention and treatment of animal diseases. It is always exciting to celebrate growth within an important existing industry, but even more gratifying when the work being done in Georgia could potentially have such a far reaching impact.”

Exclusive Research